Skip to content

Pharminent

cropped-neurology_aaic_banner_frontpage_2026-07-15-1.png
Primary Menu
  • Home
  • Signal News
  • Biopharma Brief
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Interactive Calendar
    • Manufacturing Intelligence
  • Contact
Light/Dark Button
Brief
  • Home
  • Pipeline
  • Sanofi drops two more programmes in R&D clear-out
  • Pipeline

Sanofi drops two more programmes in R&D clear-out

Pharmaphorum

Shortly after terminating one late-stage R D programme, Sanofi confirmed in its second-quarter update that two others are being scrapped.

Read full story

pharminent July 30, 2026 (Last updated: August 3, 2026)

Pharmaphorum

Shortly after terminating one late-stage R D programme, Sanofi confirmed in its second-quarter update that two others are being scrapped.

Read full story

Sign up to receive free daily digest

Check your inbox or spam folder to confirm your subscription.

Post navigation

Previous: GSK Cambridge Move Signals Shift in Drug Scale-Up Strategy
Next: Amgen’s Repatha Wins Positive CHMP Opinion for Preventing First Heart Attacks and Strokes

Related Stories

  • Pipeline

Lundbeck preps for key bexicaserin data around year-end

pharminent July 20, 2026
  • Pipeline

AAIC 2026: Tau-targeted Alzheimer’s treatments heat up while amyloid therapies persist

pharminent July 10, 2026
  • Pipeline

Roche scraps two Ionis-partnered Huntington’s drugs

pharminent July 9, 2026
© 2026 All rights reserved. | ReviewNews by AF themes.